An updated consensus statement from the American Diabetes Association (ADA) and European Association for the Study of Diabetes (EASD) addressed social drivers of health, lifestyle modifications, and new drug classes for type 2 diabetes.
14 Oct 2022
Gestational diabetes associated with risks later in life, but lifestyle makes a difference, studies find
A review found increased risks of cardiovascular and cerebrovascular disease in women who had gestational diabetes, while another study showed that five markers of a healthy lifestyle were associated with a significant reduction in risk of developing type 2 diabetes after gestational diabetes.
14 Oct 2022
A cohort study in the United Kingdom found that chronic obstructive pulmonary disease (COPD) exacerbations were less common in patients with type 2 diabetes and COPD taking glucagon-like peptide-1 receptor agonists or sodium-glucose cotransporter-2 inhibitors versus sulfonylureas.
11 Nov 2022
In a small trial, patients with insulin-treated diabetes were randomly assigned to usual care, a lottery incentive for daily self-monitored blood glucose, or the lottery plus support from a community health worker if needed.
10 Jun 2022
A prospective registry-based study in Denmark found that offspring of men who filled one or more prescriptions for metformin during the three months of developing fertilizing sperm were more likely to have a birth defect, while insulin and sulfonylureas were not associated with increased risk.
8 Apr 2022
Researchers used data from the National Health and Nutrition Examination Survey to determine the body mass index and age thresholds for diabetes screening in major racial/ethnic minority populations.
13 May 2022
A systematic review found that HbA1c levels were improved significantly by food supplementation with referral and diabetes support, financial incentives with education and skills training, housing relocation with counseling support, and the integration of nonmedical interventions into medical care.
8 Jul 2022
Amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin were similarly effective for controlling pain, a recent study found.
16 Sep 2022
A new guideline from The BMJ strongly recommends sodium-glucose cotransporter-2 (SGLT-2) inhibitors for patients with diabetes and established cardiovascular and chronic kidney disease, in addition to offering weaker support for starting glucagon-like peptide-1 (GLP-1) receptor agonists in this same patient population.
11 Jun 2021
The trial was stopped early after an interim safety analysis found significantly better renal and cardiovascular outcomes among type 2 diabetes patients randomized to canagliflozin than those assigned to placebo.
10 May 2019